Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
Guangjun Wang,Yinghua Tan,Yongjie Jiang,Jia Liu,Yuanhui Su,Zhengang Sun,Bo Liu
DOI: https://doi.org/10.2147/RMHP.S413052
2023-07-11
Risk Management and Healthcare Policy
Abstract:Guangjun Wang, 1, &ast Yinghua Tan, 2, &ast Yongjie Jiang, 1 Jia Liu, 1 Yuanhui Su, 3 Zhengang Sun, 4 Bo Liu 3, 5 1 Department of General Surgery, Qingdao West Coast New Area Central Hospital, Qingdao, Shandong, People's Republic of China; 2 Department of Paediatrics, Qingdao West Coast New Area Central Hospital, Qingdao, Shandong, People's Republic of China; 3 Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, People's Republic of China; 4 Department of Spine Surgery, Qingdao West Coast New Area Central Hospital, Qingdao, Shandong, People's Republic of China; 5 Department of Gastrointestinal Surgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bo Liu, Email Purpose: The AJCC (the American Joint Committee on Cancer) ypTNM (post-neoadjuvant pathologic stage group) staging was established based on patients with lymphadenectomy scope less than D2 and did not include ypT0N0 patients with pathologically complete response (PCR). The purpose of this study was to construct a survival predictive model for gastric cancer patients after neoadjuvant chemotherapy and gastrectomy combined with D2 lymphadenectomy. Patients and Methods: The multicenter data of 838 gastric cancer patients who received neoadjuvant chemotherapy and gastrectomy combined with D2 lymphadenectomy were analyzed retrospectively. These dual center patients were divided into training (n = 671, the Affiliated Hospital of Qingdao University) and validation (n = 167, Qingdao West Coast New Area Central Hospital) cohorts. Based on training cohort, univariate and multivariable COX regression analyses were performed to select the clinicopathological characteristics significantly correlating with overall survival and construct a nomogram. Based on training and validation cohorts, the distinguishing and calibrating capabilities of nomogram was evaluated by the receiver operating characteristic (ROC) curve, Harrell's concordance index (C-index), decision curve analysis (DCA) curve and calibration curve. Results: Platelet-to-lymphocyte ratio (PLR), pathologic stage after neoadjuvant treatment: ypT and ypN stage, tumor regression grade (TRG) became independent variables intimately related to the prognosis and was used to construct nomograms of 3/5-year prognosis. The nomograms showed an accuracy in predicting OS (overall survival) rate, with area under the ROC curve (AUC) of 0.818 (95% CI = 0.753~0.883) and C-index of 0.801 (95% CI = 0.744~0.858) in validation cohort. Calibration curves showed satisfactory agreement between nomogram prediction and actual result, and DCA curves indicated the large positive net benefit and excellent clinical usefulness of nomogram. Conclusion: This study successfully developed a nomogram to predict overall survival of gastric cancer patients after neoadjuvant chemotherapy and gastrectomy combined with D2 lymphadenectomy, which might have excellent predictive performance and clinical application value. Keywords: gastric cancer, neoadjuvant therapy, gastrectomy, nomogram, survival analysis Nowadays, neoadjuvant chemotherapy and gastrectomy combined with D2 lymphadenectomy has been widely used in the treatment of advanced gastric cancer. 1–3 Compared with surgery merely, combined neoadjuvant chemotherapy can prolong survival rate, reduce tumor staging, and improve radical resection (R0 resection) rate. The timing and method of surgery can be selected according to the reaction degree after neoadjuvant chemotherapy, so as to achieve D2 lymphadenectomy as far as possible. 4,5 However, patients have different prognosis due to individual differences, and affect postoperative treatment decisions. 6–8 Therefore, patients receiving neoadjuvant chemotherapy combined with D2 radical gastrectomy for gastric cancer need more accurate prognosis prediction to guide treatment. Many previous studies have utilized clinicopathological factors as prognostic factors, but most prognostic factors are still limited and controversial. 9–14 AJCC (the American Joint Committee on Cancer) ypTNM (post-neoadjuvant pathologic stage group) staging is the most authoritative guideline prognostic system for gastric cancer patients receiving neoadjuvant chemotherapy. 2,15 However, this system was established based on patients with lymphadenectomy scope less than D2 and did not include ypT0N0 patients with pathologically complete response (PCR), so it may not be suitable for patients with D2 radical gastrectomy or pathol -Abstract Truncated-
health care sciences & services,health policy & services